{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:41:14Z","timestamp":1790847674530,"version":"4.1.0"},"reference-count":109,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T00:00:00Z","timestamp":1600300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001703","name":"\u00c9cole Polytechnique F\u00e9d\u00e9rale de Lausanne","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001703","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Michael J Fox Foundation"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.nbd.2020.105086","type":"journal-article","created":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T22:33:10Z","timestamp":1600727590000},"page":"105086","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":162,"special_numbering":"C","title":["How specific are the conformation-specific \u03b1-synuclein antibodies? Characterization and validation of 16 \u03b1-synuclein conformation-specific antibodies using well-characterized preparations of \u03b1-synuclein monomers, fibrils and oligomers with distinct structures and morphology"],"prefix":"10.1016","volume":"146","author":[{"given":"Senthil T.","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somanath","family":"Jagannath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Francois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Vanderstichele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Stoops","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7682-8320","authenticated-orcid":false,"given":"Hilal A.","family":"Lashuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nbd.2020.105086_bb0005","unstructured":"abcamCat.No.ab209538 Recombinant Anti-Alpha-synuclein aggregate antibody [MJFR-14-6-4-2] - Conformation-Specific (ab209538)."},{"key":"10.1016\/j.nbd.2020.105086_bb0010","unstructured":"AgriseraCat.No.AS132718 ASyO5 | Mouse anti-human alpha-synuclein | oligomer-specific (clone number 2.4)s."},{"key":"10.1016\/j.nbd.2020.105086_bb0015","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1038\/s41591-019-0611-3","article-title":"Resistance to autosomal dominant Alzheimer\u2019s disease in an APOE3 Christchurch homozygote: A case report","volume":"25","author":"Arboleda-Velasquez","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.nbd.2020.105086_bb0020","first-page":"879","article-title":"Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson\u2019s disease and dementia with Lewy bodies","volume":"152","author":"Baba","year":"1998","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.nbd.2020.105086_bb0025","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1089\/ars.2011.4429","article-title":"Lipid peroxidation product 4-hydroxy-2-nonenal promotes seeding-capable oligomer formation and cell-to-cell transfer of \u03b1-synuclein","volume":"18","author":"Bae","year":"2013","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.nbd.2020.105086_bb0030","doi-asserted-by":"crossref","first-page":"15610","DOI":"10.1021\/bi061743l","article-title":"Alpha-synuclein adopts an alpha-helical conformation in the presence of polyunsaturated fatty acids to hinder micelle formation","volume":"45","author":"Broersen","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.nbd.2020.105086_bb0035","first-page":"1377","article-title":"Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway","volume":"19","author":"Cappai","year":"2005","journal-title":"FASEB J. Off. Publ. Feder. Am. Soc. Exp. Biol."},{"key":"10.1016\/j.nbd.2020.105086_bb0040","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1073\/pnas.1218424110","article-title":"Large \u03b1-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking","volume":"110","author":"Choi","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.nbd.2020.105086_bb0045","doi-asserted-by":"crossref","first-page":"9678","DOI":"10.1074\/jbc.M409946200","article-title":"Metal-catalyzed oxidation of alpha-synuclein: Helping to define the relationship between oligomers, protofibrils, and filaments","volume":"280","author":"Cole","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2020.105086_bb0050","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1523\/JNEUROSCI.5367-11.2012","article-title":"Endoplasmic reticulum stress is important for the manifestations of \u03b1-synucleinopathy in vivo","volume":"32","author":"Colla","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2020.105086_bb0055","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1136\/jnnp.74.7.852","article-title":"Lewy body cortical involvement may not always predict dementia in Parkinson\u2019s disease","volume":"74","author":"Colosimo","year":"2003","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.nbd.2020.105086_bb0060","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1073\/pnas.97.2.571","article-title":"Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson\u2019s disease: Implications for pathogenesis and therapy","volume":"97","author":"Conway","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2020.105086_bb0065","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1126\/science.1063522","article-title":"Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct","volume":"294","author":"Conway","year":"2001","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.nbd.2020.105086_bb0070","first-page":"217","article-title":"Genetic neuropathology of Parkinson\u2019s disease","volume":"1","author":"Cookson","year":"2008","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.nbd.2020.105086_bb0075","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/nan.12402","article-title":"Novel conformation-selective alpha-synuclein antibodies raised against different in vitro fibril forms show distinct patterns of Lewy pathology in Parkinson\u2019s disease","volume":"43","author":"Covell","year":"2017","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.nbd.2020.105086_bb0080","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/bs.ircmb.2016.08.010","article-title":"Structural characteristics of alpha-synuclein oligomers","volume":"329","author":"Cremades","year":"2017","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"10.1016\/j.nbd.2020.105086_bb0085","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1126\/science.1101738","article-title":"Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy","volume":"305","author":"Cuervo","year":"2004","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.nbd.2020.105086_bb0090","doi-asserted-by":"crossref","first-page":"9220","DOI":"10.1523\/JNEUROSCI.2617-07.2007","article-title":"Different species of alpha-synuclein oligomers induce calcium influx and seeding","volume":"27","author":"Danzer","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2020.105086_bb0095","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1471-4159.2009.06324.x","article-title":"Seeding induced by \u03b1-synuclein oligomers provides evidence for spreading of \u03b1-synuclein pathology","volume":"111","author":"Danzer","year":"2009","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2020.105086_bb0100","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1750-1326-7-42","article-title":"Exosomal cell-to-cell transmission of alpha synuclein oligomers","volume":"7","author":"Danzer","year":"2012","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.nbd.2020.105086_bb0105","doi-asserted-by":"crossref","first-page":"22262","DOI":"10.1074\/jbc.M110.202937","article-title":"Structural and morphological characterization of aggregated species of alpha-synuclein induced by docosahexaenoic acid","volume":"286","author":"De Franceschi","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2020.105086_bb0110","doi-asserted-by":"crossref","first-page":"13010","DOI":"10.1073\/pnas.0903691106","article-title":"Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein","volume":"106","author":"Desplats","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2020.105086_bb0115","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1126\/scitranslmed.aaf3634","article-title":"Alpha-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson\u2019s disease","volume":"8","author":"Di Maio","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.nbd.2020.105086_bb0120","doi-asserted-by":"crossref","first-page":"11750","DOI":"10.1523\/JNEUROSCI.0234-12.2012","article-title":"Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation","volume":"32","author":"Di\u00f3genes","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2020.105086_bb0125","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/00005072-196507000-00003","article-title":"Phase and Electron microscopic observations of Lewy bodies and melanin granules in the substantia nigra and locus caeruleus in Parkinson\u2019s disease*\u2020","volume":"24","author":"Duffy","year":"1965","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.nbd.2020.105086_bb0130","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nsmb.1437","article-title":"EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers","volume":"15","author":"Ehrnhoefer","year":"2008","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.nbd.2020.105086_bb0135","first-page":"419","article-title":"Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson\u2019s disease","volume":"20","author":"El-Agnaf","year":"2006","journal-title":"FASEB J. Off. Publ. Feder. Am. Soc. Exp. Biol"},{"key":"10.1016\/j.nbd.2020.105086_bb0140","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s40478-019-0865-5","article-title":"Organotypic slice culture model demonstrates inter-neuronal spreading of alpha-synuclein aggregates","volume":"7","author":"Elfarrash","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.nbd.2020.105086_bb0145","doi-asserted-by":"crossref","first-page":"15345","DOI":"10.1074\/jbc.M111.318949","article-title":"Alpha-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer","volume":"287","author":"Fauvet","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2020.105086_bb0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0082732","article-title":"\u03b1-synuclein oligomers induced by docosahexaenoic acid affect membrane integrity","volume":"8","author":"Fecchio","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2020.105086_bb0155","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.neurobiolaging.2009.05.019","article-title":"Incidental Lewy body disease: do some cases represent a preclinical stage of dementia with Lewy bodies?","volume":"32","author":"Frigerio","year":"2011","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.nbd.2020.105086_bb0160","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1001\/archneur.63.3.377","article-title":"LRRK2 mutations in Spanish patients with Parkinson disease: Frequency, clinical features, and incomplete penetrance","volume":"63","author":"Gaig","year":"2006","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.nbd.2020.105086_bb0165","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/(SICI)1097-4547(20000215)59:4<528::AID-JNR8>3.0.CO;2-0","article-title":"A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson\u2019s disease","volume":"59","author":"Giasson","year":"2000","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.nbd.2020.105086_bb0170","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.3233\/JPD-179005","article-title":"The synucleinopathies: Twenty years on","volume":"7","author":"Goedert","year":"2017","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.nbd.2020.105086_bb0175","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.48907","article-title":"Two new polymorphic structures of human full-length alpha-synuclein fibrils solved by cryo-electron microscopy","volume":"8","author":"Guerrero-Ferreira","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.nbd.2020.105086_bb0180","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cell.2013.05.057","article-title":"Distinct \u03b1-synuclein strains differentially promote tau inclusions in neurons","volume":"154","author":"Guo","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.nbd.2020.105086_bb0185","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2217\/bmm-2019-0167","article-title":"Oligomeric \u03b1-synuclein is increased in basal tears of Parkinson\u2019s patients","volume":"13","author":"Hamm-Alvarez","year":"2019","journal-title":"Biomark. Med"},{"key":"10.1016\/j.nbd.2020.105086_bb0190","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.neulet.2011.01.005","article-title":"Cerebrospinal fluid from patients with multiple system atrophy promotes in vitro alpha-synuclein fibril formation","volume":"491","author":"Hirohata","year":"2011","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.nbd.2020.105086_bb0195","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1042\/BJ20150159","article-title":"Distinct higher-order alpha-synuclein oligomers induce intracellular aggregation","volume":"468","author":"Illes-Toth","year":"2015","journal-title":"Biochem. J."},{"key":"10.1016\/j.nbd.2020.105086_bb0200","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3389\/fnins.2016.00408","article-title":"Alpha-synuclein oligomers-neurotoxic molecules in Parkinson\u2019s disease and other Lewy body disorders","volume":"10","author":"Ingelsson","year":"2016","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.nbd.2020.105086_bb0205","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/j.1471-4159.2010.06695.x","article-title":"Non-classical exocytosis of alpha-synuclein is sensitive to folding states and promoted under stress conditions","volume":"113","author":"Jang","year":"2010","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2020.105086_bb0210","series-title":"Case reports in neurological medicine 2018","first-page":"6838965","article-title":"A case of Parkinson\u2019s disease with no Lewy body pathology due to a homozygous exon deletion in parkin","author":"Johansen","year":"2018"},{"key":"10.1016\/j.nbd.2020.105086_bb0215","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/ene.12761","article-title":"Regional beta-amyloid burden does not correlate with cognitive or language deficits in Alzheimer\u2019s disease presenting as aphasia","volume":"23","author":"Jung","year":"2016","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.nbd.2020.105086_bb0220","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1113\/JP271968","article-title":"Intracellular soluble alpha-synuclein oligomers reduce pyramidal cell excitability","volume":"594","author":"Kaufmann","year":"2016","journal-title":"J. Physiol."},{"key":"10.1016\/j.nbd.2020.105086_bb0225","doi-asserted-by":"crossref","first-page":"5358","DOI":"10.3390\/ijms20215358","article-title":"Fatty acid-binding protein 3 is critical for \u03b1-synuclein uptake and MPP(+)-induced mitochondrial dysfunction in cultured dopaminergic neurons","volume":"20","author":"Kawahata","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.nbd.2020.105086_bb0230","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/mds.20618","article-title":"Escaping Parkinson\u2019s disease: A neurologically healthy octogenarian with the LRRK2 G2019S mutation","volume":"20","author":"Kay","year":"2005","journal-title":"Movement Disord. Off. J. Movem. Disord. Soc."},{"key":"10.1016\/j.nbd.2020.105086_bb0235","doi-asserted-by":"crossref","first-page":"754","DOI":"10.4161\/auto.19371","article-title":"Alpha-synuclein aggregation involves a bafilomycin A 1-sensitive autophagy pathway","volume":"8","author":"Klucken","year":"2012","journal-title":"Autophagy"},{"key":"10.1016\/j.nbd.2020.105086_bb0240","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00401-012-0964-x","article-title":"An antibody with high reactivity for disease-associated alpha-synuclein reveals extensive brain pathology","volume":"124","author":"Kovacs","year":"2012","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.nbd.2020.105086_bb0245","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1515\/cclm-2015-1195","article-title":"Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa","volume":"54","author":"Kuhle","year":"2016","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.nbd.2020.105086_bb0250","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/jnc.14955","article-title":"A simple, versatile and robust centrifugation-based filtration protocol for the isolation and quantification of alpha-synuclein monomers, oligomers and fibrils: Towards improving experimental reproducibility in alpha-synuclein research","volume":"153","author":"Kumar","year":"2020","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2020.105086_bb0255","author":"Kumar","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.nbd.2020.105086_bb0260","article-title":"Do Lewy bodies contain alpha-synuclein fibrils? And does it matter? A brief history and critical analysis of recent reports","volume":"104876","author":"Lashuel","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2020.105086_bb0265","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1017\/S0033583506004422","article-title":"Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins?","volume":"39","author":"Lashuel","year":"2006","journal-title":"Q. Rev. Biophys."},{"key":"10.1016\/j.nbd.2020.105086_bb0270","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0022-2836(02)00735-0","article-title":"Alpha-synuclein, especially the Parkinson\u2019s disease-associated mutants, forms pore-like annular and tubular protofibrils","volume":"322","author":"Lashuel","year":"2002","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.nbd.2020.105086_bb0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196056","article-title":"ELISA method to detect \u03b1-synuclein oligomers in cell and animal models","volume":"13","author":"Lassen","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2020.105086_bb0280","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.biocel.2008.01.017","article-title":"Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein","volume":"40","author":"Lee","year":"2008","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.nbd.2020.105086_bb0285","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1007\/s11064-009-9986-8","article-title":"Modulation of alpha-synuclein aggregation by dopamine: A review","volume":"34","author":"Leong","year":"2009","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.nbd.2020.105086_bb0290","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1038\/s41467-018-05971-2","article-title":"Cryo-EM of full-length \u03b1-synuclein reveals fibril polymorphs with a common structural kernel","volume":"9","author":"Li","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.nbd.2020.105086_bb0295","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1110\/ps.04879704","article-title":"Calcium(II) selectively induces alpha-synuclein annular oligomers via interaction with the C-terminal domain","volume":"13","author":"Lowe","year":"2004","journal-title":"Protein Sci. Publ. Protein Soc."},{"key":"10.1016\/j.nbd.2020.105086_bb0300","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1038\/cdd.2015.79","article-title":"Fibril growth and seeding capacity play key roles in alpha-synuclein-mediated apoptotic cell death","volume":"22","author":"Mahul-Mellier","year":"2015","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.nbd.2020.105086_bb0305","first-page":"500058","article-title":"The making of a Lewy body: The role of \u03b1-synuclein post-fibrillization modifications in regulating the formation and the maturation of pathological inclusions","author":"Mahul-Mellier","year":"2018","journal-title":"bioRxiv"},{"key":"10.1016\/j.nbd.2020.105086_bb0310","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1073\/pnas.1913904117","article-title":"The process of Lewy body formation, rather than simply \u03b1-synuclein fibrillization, is one of the major drivers of neurodegeneration","volume":"117","author":"Mahul-Mellier","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.nbd.2020.105086_bb0315","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13024-016-0072-9","article-title":"Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson\u2019s disease","volume":"11","author":"Majbour","year":"2016","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.nbd.2020.105086_bb0320","series-title":"The Michael J. Fox Foundation\u2019s Strategy to Generate, Characterize, and Distribute Preclinical Alpha-Synuclein Research Tools for Molecular Biology","author":"Martinez","year":"2016"},{"key":"10.1016\/j.nbd.2020.105086_bb0325","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1038\/nn.4641","article-title":"Dopamine induces soluble alpha-synuclein oligomers and nigrostriatal degeneration","volume":"20","author":"Mor","year":"2017","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.nbd.2020.105086_bb0330","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.bbrc.2008.12.005","article-title":"The lipid peroxidation metabolite 4-oxo-2-nonenal cross-links alpha-synuclein causing rapid formation of stable oligomers","volume":"378","author":"Nasstrom","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.nbd.2020.105086_bb0335","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.freeradbiomed.2010.11.027","article-title":"The lipid peroxidation products 4-oxo-2-nonenal and 4-hydroxy-2-nonenal promote the formation of \u03b1-synuclein oligomers with distinct biochemical, morphological, and functional properties","volume":"50","author":"N\u00e4sstr\u00f6m","year":"2011","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.nbd.2020.105086_bb0340","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027230","article-title":"Antibodies against alpha-synuclein reduce oligomerization in living cells","volume":"6","author":"N\u00e4sstr\u00f6m","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2020.105086_bb0345","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","article-title":"Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature","volume":"71","author":"Nelson","year":"2012","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.nbd.2020.105086_bb0350","doi-asserted-by":"crossref","first-page":"21212","DOI":"10.1074\/jbc.M412621200","article-title":"Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations","volume":"280","author":"Norris","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2020.105086_bb0355","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1093\/brain\/awn349","article-title":"Detection of elevated levels of soluble \u03b1-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies","volume":"132","author":"Paleologou","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.nbd.2020.105086_bb0360","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/j.biocel.2009.05.008","article-title":"Alpha-synuclein overexpression and aggregation exacerbates impairment of mitochondrial functions by augmenting oxidative stress in human neuroblastoma cells","volume":"41","author":"Parihar","year":"2009","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.nbd.2020.105086_bb0365","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ana.20321","article-title":"Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia","volume":"57","author":"Parkkinen","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2020.105086_bb0370","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00401-008-0346-6","article-title":"Applicability of current staging\/categorization of alpha-synuclein pathology and their clinical relevance","volume":"115","author":"Parkkinen","year":"2008","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.nbd.2020.105086_bb0375","doi-asserted-by":"crossref","first-page":"6252","DOI":"10.1021\/bi5007833","article-title":"High stability and cooperative unfolding of alpha-synuclein oligomers","volume":"53","author":"Paslawski","year":"2014","journal-title":"Biochemistry"},{"key":"10.1016\/j.nbd.2020.105086_bb0380","doi-asserted-by":"crossref","first-page":"7560","DOI":"10.1002\/anie.201400491","article-title":"Co-existence of two different \u03b1-synuclein oligomers with different core structures determined by hydrogen\/deuterium exchange mass spectrometry","volume":"53","author":"Paslawski","year":"2014","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.nbd.2020.105086_bb0385","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/978-1-4939-2978-8_9","article-title":"Formation and characterization of alpha-synuclein oligomers","volume":"1345","author":"Paslawski","year":"2016","journal-title":"Methods Mol. Biol. (Clifton, N.J.)"},{"key":"10.1016\/j.nbd.2020.105086_bb0390","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0304-3940(03)00781-X","article-title":"Epitope mapping and specificity of the anti-alpha-synuclein monoclonal antibody Syn-1 in mouse brain and cultured cell lines","volume":"349","author":"Perrin","year":"2003","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.nbd.2020.105086_bb0395","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1002\/pro.2521","article-title":"Dopamine-induced alpha-synuclein oligomers show self- and cross-propagation properties","volume":"23","author":"Planchard","year":"2014","journal-title":"Protein Sci. Publ. Protein Soc."},{"key":"10.1016\/j.nbd.2020.105086_bb0400","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the alpha-synuclein gene identified in families with Parkinson\u2019s disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.nbd.2020.105086_bb0405","doi-asserted-by":"crossref","first-page":"5862","DOI":"10.1074\/jbc.M608126200","article-title":"Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation","volume":"282","author":"Qin","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2020.105086_bb0410","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s00249-010-0595-x","article-title":"The structure of dopamine induced alpha-synuclein oligomers","volume":"39","author":"Rekas","year":"2010","journal-title":"Eur. Biophys. J. EBJ"},{"key":"10.1016\/j.nbd.2020.105086_bb0415","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nbt.1641","article-title":"Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations","volume":"28","author":"Rissin","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.nbd.2020.105086_bb0420","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1093\/brain\/awv040","article-title":"Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson\u2019s disease brain","volume":"138","author":"Roberts","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.nbd.2020.105086_bb0425","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1093\/brain\/awu057","article-title":"Accumulation of oligomer-prone alpha-synuclein exacerbates synaptic and neuronal degeneration in vivo","volume":"137","author":"Rockenstein","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.nbd.2020.105086_bb0430","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0216764","article-title":"Stabilization of \u03b1-synuclein oligomers using formaldehyde","volume":"14","author":"Ruesink","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2020.105086_bb0435","doi-asserted-by":"crossref","first-page":"7230","DOI":"10.1073\/pnas.1721220115","article-title":"Identification and nanomechanical characterization of the fundamental single-strand protofilaments of amyloid \u03b1-synuclein fibrils","volume":"115","author":"Ruggeri","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.nbd.2020.105086_bb0440","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.cell.2016.11.018","article-title":"Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson\u2019s disease","volume":"167","author":"Sampson","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.nbd.2020.105086_bb0445","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0042545","article-title":"Single-channel electrophysiology reveals a distinct and uniform pore complex formed by alpha-synuclein oligomers in lipid membranes","volume":"7","author":"Schmidt","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2020.105086_bb0450","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/s41593-019-0423-2","article-title":"Lewy pathology in Parkinson\u2019s disease consists of crowded organelles and lipid membranes","volume":"22","author":"Shahmoradian","year":"2019","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.nbd.2020.105086_bb0455","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0896-6273(03)00024-2","article-title":"The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson\u2019s disease","volume":"37","author":"Sharon","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.nbd.2020.105086_bb0460","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.nbd.2020.105086_bb0465","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1073\/pnas.95.11.6469","article-title":"Alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson\u2019s disease and dementia with lewy bodies","volume":"95","author":"Spillantini","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2020.105086_bb0470","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s12035-012-8331-4","article-title":"\u03b1-Synuclein oligomers: An amyloid pore?","volume":"47","author":"St\u00f6ckl","year":"2013","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.nbd.2020.105086_bb0475","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1074\/jbc.R117.818237","article-title":"Chaperone-mediated autophagy and endosomal microautophagy: Joint by a chaperone","volume":"293","author":"Tekirdag","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2020.105086_bb0480","doi-asserted-by":"crossref","first-page":"44405","DOI":"10.1074\/jbc.M308041200","article-title":"Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function","volume":"278","author":"Tofaris","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2020.105086_bb0485","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1212\/WNL.0b013e3181fd613b","article-title":"Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease","volume":"75","author":"Tokuda","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2020.105086_bb0490","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1042\/BJ20051277","article-title":"Interaction with phospholipids modulates alpha-synuclein nitration and lipid-protein adduct formation","volume":"393","author":"Trostchansky","year":"2006","journal-title":"Biochem. J."},{"key":"10.1016\/j.nbd.2020.105086_bb0495","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.nano.2008.05.005","article-title":"Mechanism of alpha-synuclein oligomerization and membrane interaction: Theoretical approach to unstructured proteins studies","volume":"4","author":"Tsigelny","year":"2008","journal-title":"Nanomedicine"},{"key":"10.1016\/j.nbd.2020.105086_bb0500","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.nbd.2015.04.009","article-title":"Generation and characterization of novel conformation-specific monoclonal antibodies for alpha-synuclein pathology","volume":"79","author":"Vaikath","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2020.105086_bb0505","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0213663","article-title":"Two conformationally distinct \u03b1-synuclein oligomers share common epitopes and the ability to impair long-term potentiation","volume":"14","author":"van Diggelen","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2020.105086_bb0510","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151156","article-title":"Abnormal salivary total and oligomeric alpha-synuclein in Parkinson\u2019s disease","volume":"11","author":"Vivacqua","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2020.105086_bb0515","doi-asserted-by":"crossref","first-page":"7812","DOI":"10.1021\/bi0102398","article-title":"Vesicle permeabilization by protofibrillar alpha-synuclein: Implications for the pathogenesis and treatment of Parkinson\u2019s disease","volume":"40","author":"Volles","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.nbd.2020.105086_bb0520","doi-asserted-by":"crossref","first-page":"17797","DOI":"10.1073\/pnas.1113260108","article-title":"A soluble \u03b1-synuclein construct forms a dynamic tetramer","volume":"108","author":"Wang","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.nbd.2020.105086_bb0525","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.nbd.2018.10.016","article-title":"Development of an aggregate-selective, human-derived \u03b1-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson\u2019s disease models","volume":"124","author":"Weihofen","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2020.105086_bb0530","first-page":"1750","article-title":"CAPITO--a web server-based analysis and plotting tool for circular dichroism data","volume":"29","author":"Wiedemann","year":"2013","journal-title":"Bioinformatics (Oxford, England)"},{"key":"10.1016\/j.nbd.2020.105086_bb0535","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1177\/039463200902200405","article-title":"Suppression of MAP kinases inhibits microglial activation and attenuates neuronal cell death induced by alpha-synuclein protofibrils","volume":"22","author":"Wilms","year":"2009","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.nbd.2020.105086_bb0540","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1096\/fj.09-130039","article-title":"Unique copper-induced oligomers mediate alpha-synuclein toxicity","volume":"23","author":"Wright","year":"2009","journal-title":"FASEB J."},{"key":"10.1016\/j.nbd.2020.105086_bb0545","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.mcn.2013.01.004","article-title":"Oxidative stress-induced posttranslational modifications of alpha-synuclein: Specific modification of alpha-synuclein by 4-hydroxy-2-nonenal increases dopaminergic toxicity","volume":"54","author":"Xiang","year":"2013","journal-title":"Mol. Cell. Neurosci."}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996120303612?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996120303612?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T05:22:32Z","timestamp":1760851352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969996120303612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":109,"alternative-id":["S0969996120303612"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2020.105086","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.06.15.151514","asserted-by":"object"}]},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How specific are the conformation-specific \u03b1-synuclein antibodies? Characterization and validation of 16 \u03b1-synuclein conformation-specific antibodies using well-characterized preparations of \u03b1-synuclein monomers, fibrils and oligomers with distinct structures and morphology","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbd.2020.105086","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"105086"}}